Alexion Pharmaceuticals Inc. is targeting a new patient population with its blockbuster complement C5 inhibitor Soliris (eculizumab), patients with the ultra-rare neuromuscular condition generalized myasthenia gravis (gMG).
During the company's third quarter sales and earnings call Oct. 26, Chief Commercial Officer Brian Goff outlined some initial plans...






